Zenas BioPharma reported third-quarter 2026 results alongside progress across its autoimmune-disease pipeline. Its lead drug candidate, obexelimab, is moving through regulatory review in the United States and Europe for IgG4-related disease, while the company expects clinical updates from two other programs before year-end.
-
Cash: Zenas had $647.1 million in cash, cash equivalents and investments as of September 30, 2026.
-
U.S. review of obexelimab: The FDA accepted Zenas’ application for obexelimab for IgG4-related disease in August and set a target decision date of May 27, 2027. The application remains under review; the date is not an approval.
-
European application: Zenas’ marketing application for the same use has been validated by the European Medicines Agency, meaning it contains the required elements to proceed to scientific assessment. The application is based on results from the global Phase 3 INDIGO trial and data comparing two delivery devices.
-
Potentially more convenient delivery option: Zenas reported that obexelimab delivered by prefilled pen was bioequivalent to delivery by prefilled syringe. The company plans to submit those data in a supplemental application if the drug is approved.
-
Additional obexelimab data: Zenas said new findings presented at an international IgG4-related disease symposium support obexelimab’s potential as a reversible, steroid-sparing B-cell inhibitor. The company highlighted data related to glucocorticoid-associated toxicity and a vaccine substudy, but the release excerpt did not provide detailed results. Further open-label extension data from INDIGO are due in a late-breaking poster at ACR Convergence 2026.
-
Lupus trial: Topline results from the Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus remain on track for the fourth quarter of 2026.
-
Oral drug candidate: Dosing continues in the Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor. Zenas expects initial clinical data in the fourth quarter of 2026.
-
Multiple sclerosis program: The company presented 24-week efficacy and safety data, along with pharmacokinetic analysis, from a Phase 2 trial of orelabrutinib in relapsing-remitting multiple sclerosis. The release did not give specific numerical outcomes.
-
Leadership: Jerald Korn was appointed chief legal and strategy officer.
The principal near-term milestones are the FDA’s target decision on obexelimab in May 2027 and expected fourth-quarter 2026 clinical updates for SunStone and ZB021. The European application has entered the assessment process, but no European decision date was stated.